From Chengdu to Global: How Chengdu's Biopharma Sector Attracts Capital and Gains Prominence

Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; holds qualifications including Chinese Certified Public Accountant (CPA) and China Legal Professional Qualification. With nearly two decades of professional study in the biomedical sector, as well as experience in new drug R&D and venture capital, he has been honored with numerous titles such as “Top 30 Most Influential Young Investors of the Year,” “Top 50 Most Influential Investors of the Year,” “Young Healthcare Investor of the Year,” “Top 30 Pharmaceutical Investment Elites of the Year,” “U40 Top 40 Outstanding Young Investors,” “36U36 Investors,” and “35 Under 35 Rising Star Investors.” He has led investments in over 20 biomedical projects, with a total investment exceeding RMB 1 billion, focusing primarily on biomedicine, biotechnology, and biomanufacturing.

Chairman and General Manager of Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd.; Director of Sichuan Taihuatang Pharmaceutical Co., Ltd. Previously served as Executive Director and General Manager of Sichuan Development Hongke Equity Investment Fund Management Co., Ltd. Co-founded an internet company and secured venture capital financing. Holds an MBA from Tsinghua University, is a corporate lawyer, a non-practicing Certified Public Accountant, an Industrial Professor at Chengdu University of Traditional Chinese Medicine (Chengdu), and a member of the Biological Industry Expert Association of Chengdu High-Tech Zone. Currently primarily engaged in industrial operations, project investment, and park management within the fields of Traditional Chinese Medicine (TCM) and general health. Past investment projects have covered sub-sectors including innovative drugs, medical devices, and electronic information.

Dr. Li Yingfu has over 20 years of experience in drug R&D and management at renowned pharmaceutical companies both in China and abroad. He is the only Chinese scientist who has worked for more than a decade in new drug R&D and management at Bayer’s Global Drug Research Centers in Germany, Japan, and the United States. Upon returning to China, he successively served as Chief Scientific Officer at Yangtze River Pharmaceutical Group, General Manager and Group Vice President of Chengdu WisdomChem, and Dean of the Drug Research Institute and Group Vice President at Chengdu Better Pharmaceutical Co., Ltd. He was the primary inventor and overall project leader for multiple clinical candidate drugs. In 2019, he founded Chengdu Haibowei Pharmaceuticals, establishing distinctive technical platforms such as the “Brain-Penetrant Innovative Drug R&D Platform” to drive source innovation. Over the past six-plus years since its establishment, Haibowei Pharmaceuticals has achieved rapid, efficient, and high-quality development. The company has currently identified 11 Preclinical Candidates (PCCs), with five undergoing clinical studies and several others conducting Investigational New Drug (IND) enabling studies.

With over 14 years of experience in investment and fund management, we adhere to the core strategy of “parent-subsidiary fund synergy + full industry chain layout.” By establishing an investment system that combines a linked network of parent-subsidiary industrial funds with direct investments, we precisely target key sectors such as modern biotechnological drugs, high-performance medical devices, and innovative radiopharmaceuticals. Leveraging a dual-drive model of “investment + empowerment,” we provide deep support to enterprises throughout their entire lifecycle, from technological R&D to industrial commercialization.

Dr. Wei Jun is the Co-founder and CEO of iRegene Therapeutics, and one of the world’s first iPSC industry scientists. As a recipient of the National High-Level Talent Special Support Program and the “Huaxia Medical Science and Technology Award,” a national-level medical award, Dr. Wei has extensive expertise in chemical induction. He previously conducted frontier research in developmental biology, translational applications, and senior management at institutions including the Roslin Institute at the University of Edinburgh and Axol Bio at the University of Cambridge.